OC
LRMR icon

Oppenheimer & Co’s Larimar Therapeutics LRMR Stock Holding History

Oppenheimer & Co’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Hold
10,000
– – ﹤0.01% 1750
2026
Q1 		$45K Hold
10,000
– – ﹤0.01% 1665
2025
Q4 		$38.1K Hold
10,000
– – ﹤0.01% 1518
2025
Q3 		$32.3K Hold
10,000
– – ﹤0.01% 1635
2025
Q2 		$28.9K Buy
+10,000
New +$23.1K ﹤0.01% 1590

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Oppenheimer & Co's LRMR Position: Q2 2026 in Review

Oppenheimer & Co held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 10,000 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Oppenheimer & Co first reported a position in LRMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $45K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Oppenheimer & Co held 10,000 shares of Larimar Therapeutics worth $30.5K as of Q2 2026.
  • Oppenheimer & Co left its Larimar Therapeutics share count unchanged in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1750 holding.
  • Oppenheimer & Co first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Oppenheimer & Co's Larimar Therapeutics position peaked at $45K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.